Prof Christine Mauz-Koerholz speaks to ecancer about the phase 2 Keynote-667 study presented at ASH 2024 which looked at pembrolizumab in children, adolescents, and young adults with low-risk Classic Hodgkin Lymphoma (cHL) and slow early response to front-line chemotherapy.

She reports that out of 84 patients with slow early response, 70% had a PET negativity and could forgo radiotherapy.

Prof Mauz-Koerholz believes that this can help save these young patients from late effects of radiotherapy such as secondary cancers and cardiovascular disease.